Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report

Gregory S Emmons1, Richard H Steingart1,2, James A Stewart1,2 and Wilson C Mertens1,2*

Abstract

Introduction: In the relapsed setting, arsenic trioxide remains the backbone of treatment. Scant literature exists regarding treatment of relapsed acute promyelocytic leukemia in patients with renal failure. To the best of our knowledge we are the first to report a safe and effective means of treatment for relapsed acute promyelocytic leukemia in the setting of advanced renal failure, employing titration of arsenic trioxide based on clinical parameters rather than arsenic trioxide levels.

Case presentation: A 33-year-old Caucasian man with a history of acute promyelocytic leukemia in remission for 3 years, as well as dialysis-dependent chronic renal failure secondary to a solitary kidney and focal segmental glomerulosclerosis and human immunodeficiency virus infection, receiving highly active antiretroviral therapy presented to our hospital with bone marrow biopsy-confirmed relapsed acute promyelocytic leukemia. Arsenic trioxide was begun at a low dose with dose escalation based only on side effect profile monitoring and not laboratory testing for induction as well as maintenance without undue toxicity. Our patient achieved and remains in complete hematologic and molecular remission as of this writing.

Conclusion: Arsenic trioxide can be used safely and effectively to treat acute promyelocytic leukemia in patients with advanced renal failure using careful monitoring of side effects rather than blood levels of arsenic to guide therapeutic dosing.

Introduction

Arsenic trioxide has been used as a treatment for leukemia since the late 1800s [1]. Since that time additional studies have been reported examining the efficacy of arsenic trioxide in relapsed acute promyelocytic leukemia (APL) [2-5], but little has been published concerning the use of this agent in patients with renal failure. Only one case report has been published reporting on the dosing, effectiveness and tolerability of arsenic trioxide therapy in a patient requiring temporary hemodialysis [6]. We report a case of a patient with end-stage chronic renal failure on daily home hemodialysis successfully treated with curative intent arsenic trioxide for relapsed APL without employing laboratory monitoring of arsenic trioxide levels during the induction, consolidation and maintenance phases of treatment in relapsed APL.

Case presentation

A 33-year-old Caucasian man presented to an outside hospital 6 years ago with pancytopenia. Comorbid conditions consisted of human immunodeficiency virus infection diagnosed 19 years ago and treated with highly active antiretroviral therapy, and an 8-year history of chronic kidney disease secondary to focal segmental glomerulosclerosis and congenital solitary kidney. Bone marrow at presentation was notable for 75% involvement with abnormal promyelocytes. Fluorescence in-situ hybridization studies and reverse transcriptase-polymerase chain reaction (RT-PCR) confirmed the t(15;17) translocation and presence of the promyelocytic leukemia (PML)-RARα translocation in the bone marrow specimens.
fusion transcript respectively; a diagnosis of APL was made. Induction therapy consisted of daunorubicin $45\text{mg}/\text{m}^2$ daily on days 1 through to 3 with cytarabine $100\text{mg}/\text{m}^2$ daily on days 1 through to 7 concurrent with all-trans retinoic acid (ATRA) $40\text{mg}/\text{m}^2$ administered twice daily. Two cycles of consolidation daunorubicin $45\text{mg}/\text{m}^2$ daily on days 1 through to 3 were subsequently administered followed by 4 months of maintenance ATRA therapy; ATRA was discontinued prematurely due to near lethal pancreatitis in the setting of marked hypertriglyceridemia associated with the drug. He achieved and remained in remission, confirmed by repeated RT-PCR, for 3 years.

He presented subsequently to our hospital with neutropenic fever, pancytopenia, and low-grade disseminated intravascular coagulation. Bone marrow aspiration demonstrated relapsed APL with $80$ to $90\%$ cellularity. The patient had been receiving hemodialysis (commenced 6 months prior to the diagnosis of his relapse) four times weekly. Complete blood counts, sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, glucose, prothrombin time, activated prothrombin time, and fibrinogen were monitored daily. The QTc duration was monitored daily via an electrocardiogram as well as pre- and post-dialysis on dialysis days for the first 2 weeks of induction. Given an observed stability of the QTc, electrocardiograms were then monitored weekly. Magnesium and potassium levels were maintained above $2.0\text{mEq}/\text{L}$ and $4.0\text{mmol}/\text{L}$ respectively. Aspartate aminotransferase and alanine aminotransferase levels were monitored weekly. Following 60 days of induction, a persistently elevated $PML-RAR\alpha$ fusion transcript was detected on RT-PCR. The dose of arsenic trioxide was then increased to $0.15\text{mg}/\text{kg}$ every other day while monitored for common side effects including QTc prolongation, hepatic dysfunction, fluid retention, electrolyte imbalances, cytopenias and constitutional changes. As arsenic trioxide concentrations were not assessed or monitored, the titration of arsenic trioxide therapy was based on toxicity profile. Based on the pharmacodynamics noted above, we suspected that residual arsenic, having accumulated in various bodily tissues, would continue to provide efficacy long after our patient’s last dosing. Consequently, consolidation consisted of single agent idarubicin followed by maintenance arsenic trioxide. Surveillance for the $PML-RAR\alpha$ fusion transcript via RT-PCR continues to suggest remission at the time of this writing.

The patient has moved from the area but remains alive and free of relapse at the time of this writing. Given his comorbidities, the patient was not felt to be a candidate for high-dose chemotherapy with stem cell support.

Discussion

There is a paucity of literature involving treatment of relapsed APL in the setting of advanced renal failure requiring dialysis and the need for surveillance of arsenic levels during the treatment process. Two cases involving the successful usage of arsenic trioxide in dialysis-dependent patients have been published to date: one involving a patient receiving hemodialysis thrice weekly whereas the other received arsenic trioxide in the setting of continuous ambulatory peritoneal dialysis; both employed serum arsenic levels $[6,7]$. Arsenic trioxide is rapidly cleared from blood; yet, only a small fraction of the daily drug dose undergoes urinary excretion, making therapy in patients with impaired renal function potentially challenging. The majority of the agent is sequestered in bodily tissues and undergoes delayed elimination over many weeks to months $[8,9]$, suggesting that excess accumulation in the serum of patients with impaired renal function is unlikely. Readily available assays measure only elemental arsenic, and although newer and more sensitive assays appropriately measure organic arsenical compounds, these are not accessible in a timely fashion. Dialysis-induced compartmental shifts further limit the value of accurate measurement of arsenic trioxide; in the treatment of toxic arsenic ingestion, post-dialysis levels may actually exceed pre-dialysis levels $[10,11]$.

In non-dialysis-dependent patients, arsenic trioxide has demonstrated efficacy during induction employing both fixed daily dosing ($10\text{mg}$ or $15\text{mg}$ daily) and weight-based dosing ($0.06$–$0.20\text{mg}/\text{kg}/\text{day}$) $[2-5]$. We adopted a ‘go low, go slow’ approach in the treatment of our patient, beginning with $0.1\text{mg}/\text{kg}$ arsenic trioxide every other day while monitoring for common side effects including: QTc prolongation, hepatic dysfunction, fluid retention, electrolyte imbalances, cytopenias and constitutional changes. As arsenic trioxide concentrations were not assessed or monitored, the titration of arsenic trioxide was based on toxicity profile. Based on the pharmacodynamics noted above, we suspected that residual arsenic, having accumulated in various bodily tissues, would continue to provide efficacy long after our patient’s last dosing. Consequently, consolidation consisted of single agent idarubicin followed by maintenance arsenic trioxide. Surveillance for the $PML-RAR\alpha$ fusion transcript via RT-PCR continues to suggest remission at the time of this writing.
Conclusion
Arsenic trioxide can be used safely and effectively to treat APL in patients with advanced renal failure. Given the difficulty in obtaining accurate serum levels of arsenic trioxide and the relative ease of monitoring for common treatment-related side effects, we suggest foregoing monitoring of arsenic trioxide levels during treatment of relapsed APL in dialysis-dependent patients. Combining a low initial dose with slow dose escalation with vigilant monitoring for common side effects provides an effective and efficient means of administering arsenic trioxide therapy.

Consent
Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
GSE and RHS cared for the patient and performed the histological evaluations of the bone marrow assessments, and interpreted the clinical laboratory data. GSE and WCM performed the literature review and wrote the manuscript; GSE, WCM, and JAS were major contributors in writing the manuscript. All authors read and approved the final manuscript.

Received: 25 May 2012 Accepted: 20 September 2012 Published: 18 October 2012

References
1. Antman KH: Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001, 6(Suppl 2):1–2.
2. Niu C, Yan H, Yu T, Sun H-P, Liu J-X, Li X-S, Wu W, Zhang F-Q, Chen Y, Zhou L, Li J-M, Zeng X-Y, Yang R-RO, Yuan M-M, Ren M-Y, Gu F-Y, Cao Q, Gu B-W, Su X-Y, Chen Q-G, Xiong S-M, Zhang T-D, Waxman S, Wang Z-Y, Chen Z, Hu J, Shen Z-X, Chen S-J: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly-diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315–3324.
3. Raffoux E, Roussello P, Poupon J, Daniel M-T, Casinat B, Delarue R, Taksin A-L, Rea D, Buzyn A, Tibi A, Lebbe G, Cimeiman P, Chomienne C, Fernand J-P, Hugues T, Dengo L, Hermine O, Domrret H: Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003, 21:2326–2334.
4. Powell B, Mozer B, Stock W, Gallager RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusiner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA: Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010, 116:3751–3757.
5. Shen Z-X, Chen G-Q, Ni J-H, Li X-S, Xiong S-M, Qui Q-Y, Zhu J, Tang W, Sun G-L, Yang K-Q, Chen Y, Zhou L, Fang Z-W, Wang Y-T, Ma J, Zhang P, Zhang T-D, Chen S-J, Chen Z, Wang Z-Y: Use of Arsenic Trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354–3360.
6. Yamamoto Y, Sasaki M, Oshimi K, Sugimoto K: Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia. Acta Haematol 2009, 122:52–53.
7. Au W-Y, Cheung GT, Yuan YW, Kumanca CR, Kwong Y-L: Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide. Arch Intern Med 2005, 165:1067–1068.
8. Douer D, Tallman M: Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005, 23:2396–2410.
9. Jianhua N, Guoqiang C, Zhixiang S, Xiushong L, Haiwei L, Yanhing H, Zhiwen F, Saijuan C, Zhenyi W, Zhu C: Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. Chin Med J 1998, 111:107–1110.
10. Smith SB, Wombolt DG, Venkatesan R: Results of hemodialysis & hemoperfusion in the treatment of acute arsenic ingestion. Clin Exp Dialysis Apheresis 1981, 5:399–404.
11. Lai MW, Boyer EW, Kleinman ME, Rodig NM, Ewald MB: Acute arsenic poisoning in two siblings. Pediatrics 2005, 116:249–257.

Cite this article as: Emmons et al.: Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report. Journal of Medical Case Reports 2012 6:355.

doi:10.1186/1752-1947-6-355

Submit your manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit